Oral Remodulin's Early PK Data Look Good
This article was originally published in The Pink Sheet Daily
Executive Summary
Pill makes gradual hiking of dosage easier.
You may also be interested in...
Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA
The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.
Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA
The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.